Efficacy of high-risk human papillomavirus genotype testing as cervical cancer screening method in a tertiary hospital of Dhaka, Bangladesh

Authors

  • Asma A. Sonia Department of Gynecological Oncology, BSMMU, Dhaka, Bangladesh
  • Ashrafunnesa Department of Gynecological Oncology, BSMMU, Dhaka, Bangladesh
  • Shirin A. Begun Department of Gynecological Oncology, BSMMU, Dhaka, Bangladesh
  • Anjuman Sultana Department of Gynecological Oncology, BSMMU, Dhaka, Bangladesh
  • Jannatul Ferdaus Department of Gynecological Oncology, BSMMU, Dhaka, Bangladesh

DOI:

https://doi.org/10.18203/2320-6012.ijrms20233832

Keywords:

HPV genotype, VIA, HR-HPV, Preinvasive lesions, Invasive lesions

Abstract

Background: The fourth most frequent gynecological malignancy worldwide is cervical cancer. Due to the high incidence of risk factors, cervical cancer is a pressing concern in Bangladesh. One of the most prevalent sexually transmitted viruses that can be chronic and can result in cervical cancer is the human papillomavirus (HPV). Investigating the epidemiology and clinical traits of this specific kind of HPV requires the identification of the high-risk (HR) HPV type. The aim of the study is to find out High risk HPV genotype (16, 18, and others) distribution among asymptomatic women and compare the diagnostic performance between the test of HR-HPV and visual inspection of cervix with acetic acid.

Methods: This cross sectional study was carried out in the Department of Gynecological Oncology, Bangabandhu Sheikh Mujib Medical University, Dhaka. A total of 300 asymptomatic women, aged 30 to 60 years, fulfilling inclusion criteria were included in this study. Study data was collected by a structured questionnaire designed for interview, clinical examination, HR-HPV genotyping, visual inspection of the cervix with acetic acid (VIA), and colposcopy of the women. HR-HPV genotyping was performed by a reverse transcriptase polymerase chain reaction.

Results: Among all of the HPV genotypes, HPV 16 (4.7%) was the most prevalent type, followed by HR-HPV (3.7%), HPV 18 (0.7%), and a combination of HPV 16 and other HR-HPV (0.3%).

Conclusions: HPV genotype can be used as an effective method for cervical cancer screening, including the identification of women at risk of cervical cancer.

 

References

Bruni L, Diaz M, Castellsagué M, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789-99.

Agorastos T, Chatzistamatiou K, Katsamagkas T, Koliopoulos G, Daponte A, Constantinidis T, Constantinidis TC, HERMES Study Group. Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology. PloS One. 2015;10(3):e0119755.

Lorincz AT, Reid RI, Jenson AB, Greenberg MD, Lancaster WA, Kurman RJ. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol. 1992;79(3):328-37.

Doorbar J, Griffin H. Refining our understanding of cervical neoplasia and its cellular origins. Papillomavirus Res. 2019;7:176-9.

Bruno MT, Scalia G, Cassaro N, Boemi S. Multiple HPV 16 infection with two strains: a possible marker of neoplastic progression. BMC Cancer. 2020;20(1):1-7.

Nessa A, Rashid MH, Jahan M, Ferdous NE, Nahar PA, Chowdhury A. Role of the HPV DNA test in follow-up of treated cervical intraepithelial neoplasia in Bangladesh. Asian Pacific J Cancer Prev. 2014;15(19):8063-7.

Xue P, Ng MTA, Qiao Y. The challenges of colposcopy for cervical cancer screening in LMICs and solutions by artificial intelligence. BMC Med. 2020;18(1):1-7.

Stoler MH, Wright Jr TC, Parvu V, Yanson K, Eckert K, Kodsi S, et al. HPV testing with 16, 18, and 45 genotyping stratifies cancer risk for women with normal cytology: data from the baseline phase of the Onclarity trial. American journal of clinica11. Park E, Kim JY, Choi S, Kim DS, Oh YL. Carcinogenic risk of human papillomavirus (HPV) genotypes and potential effects of HPV vaccines in Korea. Scientific Rep. 2019;9(1):1-9.

Wang X, Zeng Y, Huang X, Zhang Y. Prevalence and genotype distribution of human papillomavirus in invasive cervical cancer, cervical intraepithelial neoplasia, and asymptomatic women in Southeast China. BioMed Res Int. 2018;8.

Piyathilake CJ, Badiga S, Simons JL, Bell WC, Jolly PE. HPV E1 qPCR, a Low-Cost Alternative Assay to Roche Diagnostic Linear Array is Effective in Identifying Women at Risk for Developing Cervical Cancer. Int J Women's Health. 2022;14:257.

Xu H, Lin A, Shao X, Shi W, Zhang Y, Yan W. Diagnostic accuracy of high-risk HPV genotyping in women with high-grade cervical lesions: evidence for improving the cervical cancer screening strategy in China. Oncotarget. 2016;7(50):83775.

Tawe L, Grover S, Narasimhamurthy M, Moyo S, Gaseitsiwe S, Kasvosve I, Paganotti GM. Molecular detection of human papillomavirus (HPV) in highly fragmented DNA from cervical cancer biopsies using double-nested PCR. MethodsX. 2018;5:569-78.

Nahar Q, Sultana F, Alam A, Islam JY, Rahman M, Khatun F, et al. Genital human papillomavirus infection among women in Bangladesh: findings from a population-based survey. PLoS One. 2014;9(10):e107675.

Albert SO, Oguntayo OA, Samaila MO. Comparative study of visual inspection of the cervix using acetic acid (VIA) and Papanicolaou (Pap) smears for cervical cancer screening. Ecancer Med Sci. 2012;6.

Nessa A, Hussain MA, Rahman JN, Rashid MH, Muwonge R, Sankaranarayanan R. Screening for cervical neoplasia in Bangladesh using visual inspection with acetic acid. Int J Gynaecol Obstet. 2010;111(2):115-8.

Gravitt PE, Paul P, Katki HA, Vendantham H, Ramakrishna G, Sudula M, et al. Effectiveness of VIA, Pap, and HPV DNA testing in a cervical cancer screening program in a peri-urban community in Andhra Pradesh, India. PLoS One. 2010;5(10):e13711.

World Health Organization. Introducing and scaling up testing for human papillomavirus as part of a comprehensive programme for prevention and control of cervical cancer. 2020. Available at: https://www.who.int/publications/i/item/9789240015166. Accessed on 12 September 2023.

Ramshankar V, Ravindran S, Arun K, Albert K, Sri SL, Ramasubramanian L, Satyaseelan B. Impact of HPV molecular testing with partial genotyping as a feasibility study in cervical cancer community screening program in South India. J Med Virol. 2023;95(4):e28715.

Rerucha CM, Caro RJ, Wheeler VL. Cervical Cancer Screening. Am Fam Physician. 2018;97(7):441-8.

Nessa A, Nahar KN, Begum SA, Anwary SA, Hossain F, Nahar K. Comparison between visual inspection of cervix and cytology based screening procedures in Bangladesh. Asian Pac J Cancer Prev. 2013;14(12):7607-11.

Bonde JH, Sandri MT, Gary DS, Andrews JC. Clinical Utility of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Systematic Review. J Low Genit Tract Dis. 2020;24(1):1-13.

Nahar Q, Sultana F, Alam A, Islam JY, Rahman M, Khatun F, et al. Genital human papillomavirus infection among women in Bangladesh: findings from a population-based survey. PLoS One. 2014;9(10):e107675.

Yang J, Wang W, Wang Z, Wang Z, Wang Y, Wang J, et al. Prevalence, genotype distribution and risk factors of cervical HPV infection in Yangqu, China: a population-based survey of 10086 women. Human vaccines & immunotherapeutics. 2020;16(7):1645-52.

Sauvaget C, Nene BM, Jayant K, Kelkar R, Malvi SG, Shastri SS, Sankaranarayanan R. Prevalence and determinants of high-risk human papillomavirus infection in middle-aged Indian women. Sexually transmitted diseases. 2011;38(10):902-6.

Dutta S, Begum R, Mazumder D, Mandal SS, Mondal R, Biswas J, Dey B, Panda CK, Basu P. Prevalence of human papillomavirus in women without cervical cancer: a population-based study in Eastern India. Int J Gynecol Pathol. 2012;31(2):178-83.

Arora R, Kumar A, Prusty BK, Kailash U, Batra S, Das BC. Prevalence of high-risk human papillomavirus (HR-HPV) types 16 and 18 in healthy women with cytologically negative Pap smear. Eur J Obstet Gynecol Reprod Biol. 2005;121(1):104-9.

Xu H, Lin A, Shao X, Shi W, Zhang Y, Yan W. Diagnostic accuracy of high-risk HPV genotyping in women with high-grade cervical lesions: evidence for improving the cervical cancer screening strategy in China. Oncotarget. 2016;7(50):83775.

Downloads

Published

2023-12-08

How to Cite

Sonia, A. A., Ashrafunnesa, Begun, S. A., Sultana, A., & Ferdaus, J. (2023). Efficacy of high-risk human papillomavirus genotype testing as cervical cancer screening method in a tertiary hospital of Dhaka, Bangladesh. International Journal of Research in Medical Sciences, 12(1), 1–7. https://doi.org/10.18203/2320-6012.ijrms20233832

Issue

Section

Original Research Articles